Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study.
Gafos M, Brodnicki E, Desai M, McCormack S, Nutland W, Wayal S, White E, Wood G, Barber T, Bell G, Clarke A, Dolling D, Dunn D, Fox J, Haddow L, Lacey C, Nardone A, Quinn K, Rae C, Reeves I, Rayment M, White D, Apea V, Ayap W, Dewsnap C, Collaco-Moraes Y, Schembri G, Sowunmi Y, Horne R; PROUD Study Team. Gafos M, et al. Among authors: lacey c. PLoS One. 2017 Apr 20;12(4):e0175596. doi: 10.1371/journal.pone.0175596. eCollection 2017. PLoS One. 2017. PMID: 28426834 Free PMC article. Clinical Trial.
Microbicides in HIV prevention.
McCormack S, Hayes R, Lacey CJ, Johnson AM. McCormack S, et al. Among authors: lacey cj. BMJ. 2001 Feb 17;322(7283):410-3. doi: 10.1136/bmj.322.7283.410. BMJ. 2001. PMID: 11179162 Free PMC article. Review. No abstract available.
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.
McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J. McCormack S, et al. Lancet. 2010 Oct 16;376(9749):1329-37. doi: 10.1016/S0140-6736(10)61086-0. Epub 2010 Sep 17. Lancet. 2010. PMID: 20851460 Free PMC article. Clinical Trial.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON. McCormack S, et al. Among authors: lacey cj. Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9. Lancet. 2016. PMID: 26364263 Free PMC article. Clinical Trial.
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, Schembri G, Sullivan AK, Mackie N, Reeves I, Portman M, Saunders J, Fox J, Bayley J, Brady M, Bowman C, Lacey CJ, Taylor S, White D, Antonucci S, Gafos M, McCormack S, Gill ON, Dunn DT, Nardone A; PROUD Study Group. Dolling DI, et al. Among authors: lacey cj. Trials. 2016 Mar 24;17:163. doi: 10.1186/s13063-016-1286-4. Trials. 2016. PMID: 27013513 Free PMC article. Clinical Trial.
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.
Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa SC, Peng L, Yu X, Ferrari G, Seaman M, Montefiori DC, Frahm N, Tomaras GD, Stöhr W, McCormack S, Shattock RJ. Cosgrove CA, et al. Among authors: lacey cj. PLoS One. 2016 May 9;11(5):e0152038. doi: 10.1371/journal.pone.0152038. eCollection 2016. PLoS One. 2016. PMID: 27159166 Free PMC article. Clinical Trial.
Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
Murray ML, Meadows J, Doré CJ, Copas AJ, Haddow LJ, Lacey C, Jit M, Soldan K, Bennett K, Tetlow M, Nathan M, Gilson R. Murray ML, et al. Among authors: lacey c. BMC Med Res Methodol. 2018 Nov 6;18(1):125. doi: 10.1186/s12874-018-0581-z. BMC Med Res Methodol. 2018. PMID: 30400777 Free PMC article. Clinical Trial.
374 results